Mylan NV (NASDAQ:MYL) Director Robert J. Coury bought 49,859 shares of the business’s stock in a transaction that occurred on Friday, August 2nd. The shares were purchased at an average price of $20.06 per share, for a total transaction of $1,000,171.54. Following the completion of the purchase, the director now directly owns 947,194 shares of the company’s stock, valued at approximately $19,000,711.64. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of MYL opened at $18.49 on Thursday. The company has a 50 day simple moving average of $18.99. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.37 and a quick ratio of 0.77. The firm has a market capitalization of $10.23 billion, a P/E ratio of 4.04, a price-to-earnings-growth ratio of 0.95 and a beta of 1.77. Mylan NV has a 52-week low of $16.63 and a 52-week high of $39.59.
Mylan (NASDAQ:MYL) last announced its quarterly earnings results on Monday, July 29th. The company reported $1.03 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.95 by $0.08. The firm had revenue of $2.85 billion during the quarter, compared to the consensus estimate of $2.82 billion. Mylan had a return on equity of 18.93% and a net margin of 0.30%. The firm’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same period in the prior year, the company posted $1.07 earnings per share. On average, equities research analysts predict that Mylan NV will post 4.27 EPS for the current fiscal year.
Several hedge funds have recently bought and sold shares of MYL. State of New Jersey Common Pension Fund D boosted its holdings in shares of Mylan by 194.0% in the first quarter. State of New Jersey Common Pension Fund D now owns 1,700,000 shares of the company’s stock valued at $48,178,000 after acquiring an additional 1,121,745 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Mylan by 15.0% in the fourth quarter. Geode Capital Management LLC now owns 7,875,204 shares of the company’s stock valued at $215,460,000 after acquiring an additional 1,026,731 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Mylan by 3,006.8% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 984,129 shares of the company’s stock valued at $18,738,000 after acquiring an additional 952,452 shares during the period. Ion Asset Management Ltd. boosted its holdings in shares of Mylan by 67.6% in the second quarter. Ion Asset Management Ltd. now owns 2,247,231 shares of the company’s stock valued at $42,787,000 after acquiring an additional 906,555 shares during the period. Finally, FIL Ltd boosted its holdings in shares of Mylan by 14.1% in the first quarter. FIL Ltd now owns 6,468,868 shares of the company’s stock valued at $183,327,000 after acquiring an additional 799,051 shares during the period. 84.23% of the stock is owned by institutional investors and hedge funds.
A number of analysts recently weighed in on the stock. Barclays assumed coverage on shares of Mylan in a research note on Tuesday, June 11th. They set an “overweight” rating and a $26.00 target price on the stock. Citigroup set a $26.00 target price on shares of Mylan and gave the stock a “buy” rating in a research note on Wednesday, July 31st. BMO Capital Markets set a $36.00 target price on shares of Mylan and gave the stock a “buy” rating in a research note on Wednesday, May 8th. Wells Fargo & Co lowered shares of Mylan from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $33.00 to $22.00 in a research note on Tuesday, May 7th. Finally, Wolfe Research assumed coverage on shares of Mylan in a research note on Friday, July 19th. They set an “outperform” rating and a $27.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and fifteen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $31.21.
Mylan Company Profile
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Featured Story: How to start trading in the forex market?
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.